ST吉药(300108) - 2020 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was ¥648,546,128.84, a decrease of 39.15% compared to ¥1,065,807,539.96 in 2019[23]. - The net profit attributable to shareholders was -¥380,305,063.00, an improvement of 78.54% from -¥1,771,791,468.01 in the previous year[23]. - The net cash flow from operating activities was -¥141,792,383.33, a decline of 166.67% compared to ¥212,689,512.07 in 2019[23]. - The total assets at the end of 2020 were ¥2,739,752,697.28, down 15.38% from ¥3,237,850,160.93 at the end of 2019[23]. - The net assets attributable to shareholders decreased by 91.65% to ¥31,471,734.56 from ¥377,063,797.56 in 2019[23]. - The company reported a basic and diluted earnings per share of -¥0.57, improving by 78.57% from -¥2.66 in 2019[23]. - The company's total revenue for the reporting period was 648,546,128.84 yuan, a decrease of 39.15% compared to the previous year[50]. - The pharmaceutical sector generated revenue of 437,357,587.39 yuan, accounting for 67.44% of total revenue, with a year-on-year decline of 47.55%[52]. - The chemical sector contributed 211,188,541.45 yuan, representing 32.56% of total revenue, with a year-on-year decrease of 8.94%[52]. - The gross profit margin for the pharmaceutical sector was 22.75%, down 4.70% year-on-year, while the chemical sector's gross profit margin was 19.06%, down 7.12% year-on-year[54]. Operational Challenges - The company faces increased operational risks due to rising labor and logistics costs, intensified global competition, and regulatory changes in the pharmaceutical industry[7]. - The company has experienced slow receivables recovery due to changes in sales channels and increased competition in the OTC market[10]. - The company reported a significant reduction in non-operating income, with a total of -¥51,969,513.58 in 2020 compared to previous years[32]. - The company faced challenges due to the pandemic, leading to decreased sales across subsidiaries and financial constraints impacting operations[57]. Strategic Initiatives - The company plans to enhance its new product development management and carefully select R&D projects to mitigate risks associated with long and unpredictable drug approval processes[8]. - The company is committed to accelerating the launch of new products to offset declines in clinical product sales and mitigate market risks[10]. - The company aims to improve production efficiency and reduce material and energy consumption to counteract the impact of intensified competition in the chemical industry[11]. - The company is focusing on upgrading product standards and enhancing the quality of its offerings[46]. - The company plans to focus on the development of biopharmaceuticals and expand its OTC market sales, aiming to enhance product quality and service[81]. - The company aims to strengthen group management and enhance talent cultivation to support its long-term development strategy[83]. Shareholder and Dividend Policy - The company will not distribute cash dividends or issue bonus shares for the year[12]. - The company did not distribute any cash dividends for the years 2018, 2019, and 2020, maintaining a consistent policy due to ongoing losses[92]. - The company's cash dividend total for 2020 was ¥0, representing 0.00% of the net profit attributable to ordinary shareholders[92]. - The company's profit distribution plan for 2020 aligns with its articles of association, emphasizing long-term development over immediate shareholder returns[90]. Acquisitions and Investments - The company acquired 70% of Liaoning Meiluo for 28 million CNY, with a commitment for net profits of at least 400,000 CNY, 440,000 CNY, and 480,000 CNY for the years 2018, 2019, and 2020 respectively[100]. - The company plans to purchase 100% of Zhejiang Yalida for 230 million CNY, with profit commitments of 20 million CNY, 30 million CNY, and 42 million CNY for the years 2018, 2019, and 2020 respectively[102]. - The acquisition of Zhejiang Yalida is expected to enhance the company's market position and financial performance[102]. Governance and Compliance - The company has established a comprehensive governance structure to enhance operational standards and protect shareholder rights[144]. - The company maintains a transparent communication strategy with investors through various channels[144]. - The company has a strong commitment to corporate governance and compliance, as evidenced by the recent changes in its board and management[183]. - The company has not faced any penalties or rectifications during the reporting period[116]. Employee and Management Structure - The total number of employees in the company is 1,338, with 759 in production, 219 in sales, 128 in technical roles, 48 in finance, and 184 in administration[198]. - The company paid a total of 4.03 million CNY in compensation to 17 directors, supervisors, and senior management personnel in 2020[195]. - The company has implemented weekly training sessions for employees focusing on production skills and safety knowledge[200]. - The company has a talent development strategy that includes a diverse incentive system for different roles[145]. Legal and Litigation Matters - The company is currently involved in litigation with a claim amount of 26,239,200 RMB, which is still in execution[109]. - The company reached a settlement in a dispute with Haitong Hengxin Guojin involving a claim amount of 81,381,600 RMB[109]. - The company has received a civil judgment from the Jilin Changchun Intermediate People's Court, requiring repayment of 259.91 million yuan to Industrial Bank[113].